Altheogen is actively securing large contracts as the global biologics market moves toward reformulating intravenous (IV) drugs into more convenient subcutaneous (SC) forms. This trend has heightened competition around formulation‑conversion technologies.
The company disclosed that the agreement with Novartis is its fourth ALT‑B4 licensing contract signed in 2024. ALT‑B4 is a human hyaluronidase‑based hybrid enzyme platform that enables the conversion of biologics to SC delivery.
On the 2nd of the month, Altheogen announced an exclusive option and license agreement with Novartis covering the ALT‑B4 technology. Novartis intends to apply the platform to develop multiple biologic products in SC format.
The deal underscores the growing interest among major pharmaceutical companies in leveraging formulation‑switch technologies to improve patient convenience and expand market opportunities.
調査・レポート2026年9月14日•3分で読めます
Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.
Pharmacountryチームがまとめました · 出典： KPA News
トピック：
評価
(0)
(0)
(0)
(0)
(0)
評価を残す